Addario Lung Cancer Medical Institute (ALCMI)
@alcmi.bsky.social
The Addario Lung Cancer Medical Institute (ALCMI) is a non-profit international consortium comprised of over 25 of the world's premier oncology research institutions. We fund and support investigator-led lung cancer clinical trials.
ERBB2 signaling emerges as a central driver of immune evasion and immunotherapy resistance in small cell lung cancer, as demonstrated by Lydia Meder, Charlotte Isabelle Orschel, and colleagues in Nature Communications. #lungcancer
www.nature.com/articles/s41...
www.nature.com/articles/s41...
ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer - Nature Communications
While the emergence of immune checkpoint inhibitors has improved outcomes in patients with small cell lung cancer (SCLC), tumour that develop means of immune evasion become resistant. Here, the…
www.nature.com
December 18, 2025 at 3:03 PM
ERBB2 signaling emerges as a central driver of immune evasion and immunotherapy resistance in small cell lung cancer, as demonstrated by Lydia Meder, Charlotte Isabelle Orschel, and colleagues in Nature Communications. #lungcancer
www.nature.com/articles/s41...
www.nature.com/articles/s41...
EGFR‑mutated lung cancer has become a true sequencing challenge, not a single‑TKI story, as outlined by Girindra Raval, MD, of the Georgia Cancer Center in a recent Cancer Network interview. #lungcancer
www.cancernetwork.com/view/surveyi...
www.cancernetwork.com/view/surveyi...
Surveying the Treatment Landscape for EGFR-Mutated Lung Cancer | CancerNetwork
An oncologist at the Georgia Cancer Center discussed the evolution of treatment strategies and emerging therapies for patients with EGFR-mutated disease.
www.cancernetwork.com
December 17, 2025 at 3:01 PM
EGFR‑mutated lung cancer has become a true sequencing challenge, not a single‑TKI story, as outlined by Girindra Raval, MD, of the Georgia Cancer Center in a recent Cancer Network interview. #lungcancer
www.cancernetwork.com/view/surveyi...
www.cancernetwork.com/view/surveyi...
Dr. Thomas Marron, in conversation with CURE Today, outlined how therapeutic cancer vaccines could shift lung cancer care by targeting micrometastatic disease and harnessing durable immune memory in the adjuvant setting. #lungcancer
www.curetoday.com/view/how-the...
www.curetoday.com/view/how-the...
How Therapeutic Vaccines May Transform Lung Cancer Care | CURE
Dr. Thomas Marron explains how therapeutic vaccines differ from preventative vaccines in lung cancer care.
www.curetoday.com
December 16, 2025 at 3:02 PM
Dr. Thomas Marron, in conversation with CURE Today, outlined how therapeutic cancer vaccines could shift lung cancer care by targeting micrometastatic disease and harnessing durable immune memory in the adjuvant setting. #lungcancer
www.curetoday.com/view/how-the...
www.curetoday.com/view/how-the...
This will be fascinating to watch! CorriXR Therapeutics and ChristianaCare Gene Editing Institute have launched an effort to develop an inhaled CRISPR therapy for lung cancer, in partnership with InhaTarget Therapeutics and MERXIN Ltd. #lungcancer
news.christianacare.org/2025/12/corr...
news.christianacare.org/2025/12/corr...
CorriXR Launches Bold Collaboration to Create First Inhaled CRISPR Therapy for Lung Cancer - ChristianaCare News
CorriXR Therapeutics, ChristianaCare’s first commercial biotherapeutics spinout, has launched a major collaboration with InhaTarget Therapeutics and Merxin Ltd to develop an inhaled genetic therapy…
news.christianacare.org
December 15, 2025 at 3:01 PM
This will be fascinating to watch! CorriXR Therapeutics and ChristianaCare Gene Editing Institute have launched an effort to develop an inhaled CRISPR therapy for lung cancer, in partnership with InhaTarget Therapeutics and MERXIN Ltd. #lungcancer
news.christianacare.org/2025/12/corr...
news.christianacare.org/2025/12/corr...
A new review crystallizes an emerging consensus that dormant lung cancer cells are not just quiescent passengers but epigenetically programmed survivors that drive minimal residual disease, therapeutic resistance, and relapse in both SCLC and NSCLC. #lungcancer
Unlocking Lung Cancer Cell Dormancy: An Epigenetic Perspective
This review summarizes current advances in understanding the epigenetic regulation of cellular dormancy in lung cancer, with a particular emphasis on the interplay between epigenetic modifiers and oncogenic signaling pathways.
www.mdpi.com
December 14, 2025 at 3:01 PM
A new review crystallizes an emerging consensus that dormant lung cancer cells are not just quiescent passengers but epigenetically programmed survivors that drive minimal residual disease, therapeutic resistance, and relapse in both SCLC and NSCLC. #lungcancer
SRSF3 knockdown induces robust, mutation-agnostic cellular senescence in NSCLC models, pointing to a new therapeutic strategy. #lungcancer
academic.oup.com/carcin/artic...
academic.oup.com/carcin/artic...
SRSF3 knockdown-induced cellular senescence as a possible therapeutic strategy for non-small cell lung cancer
Abstract. Tyrosine kinase (TK) inhibitors improve clinical outcomes in non-small cell lung cancer (NSCLC) with targetable mutations. However, such NSCLC ca
academic.oup.com
December 13, 2025 at 3:02 PM
SRSF3 knockdown induces robust, mutation-agnostic cellular senescence in NSCLC models, pointing to a new therapeutic strategy. #lungcancer
academic.oup.com/carcin/artic...
academic.oup.com/carcin/artic...
The CONFIRM study delivers compelling evidence that integrating shape-sensing robotic bronchoscopy with mobile cone-beam CT achieves high diagnostic yields for small pulmonary nodules. #lungcancer
thorax.bmj.com/content/earl...
thorax.bmj.com/content/earl...
Shape-sensing robotic-assisted bronchoscopy with integrated mobile cone-beam CT for small nodules: results from the prospective multicentre CONFIRM study
The first prospective multicentre study of integrated ssRAB and mCBCT for small peripheral nodules resulted in diagnostic outcomes similar to those reported for transthoracic biopsy with a more favourable safety profile.
thorax.bmj.com
December 12, 2025 at 3:03 PM
The CONFIRM study delivers compelling evidence that integrating shape-sensing robotic bronchoscopy with mobile cone-beam CT achieves high diagnostic yields for small pulmonary nodules. #lungcancer
thorax.bmj.com/content/earl...
thorax.bmj.com/content/earl...
Hackensack Meridian Health's Hennessy Institute and DELFI Diagnostics, backed by an Eli Lilly and Company grant, are investigating whether a blood test can improve adherence to lung cancer screening. #lungcancer
www.hackensackmeridianhealth.org/en/news/2025...
www.hackensackmeridianhealth.org/en/news/2025...
Hackensack Meridian Health Partners with DELFI Diagnostics to Improve Lung Cancer Screening Adherence with Innovative Blood Test
Initiative funded by a Healthcare Improvement grant from Eli Lilly and Company aims to increase uptake of life-saving LDCT scans for high-risk individuals in line with guidance through the use of a…
www.hackensackmeridianhealth.org
December 11, 2025 at 3:02 PM
Hackensack Meridian Health's Hennessy Institute and DELFI Diagnostics, backed by an Eli Lilly and Company grant, are investigating whether a blood test can improve adherence to lung cancer screening. #lungcancer
www.hackensackmeridianhealth.org/en/news/2025...
www.hackensackmeridianhealth.org/en/news/2025...
Congrats to all of the grant recipients! The Lung Cancer Research Foundation (LCRF) has announced its 2025 Scientific Research Grant Awards, committing $1.65 million to eleven new research projects. #lungcancer
www.prnewswire.com/news-release...
www.prnewswire.com/news-release...
Lung Cancer Research Foundation Announces 2025 Scientific Research Grant Awards
/PRNewswire/ -- The Lung Cancer Research Foundation® (LCRF) awarded its annual 2025 Scientific Grant Program awards, funding another $1.65 million in new...
www.prnewswire.com
December 10, 2025 at 3:03 PM
Congrats to all of the grant recipients! The Lung Cancer Research Foundation (LCRF) has announced its 2025 Scientific Research Grant Awards, committing $1.65 million to eleven new research projects. #lungcancer
www.prnewswire.com/news-release...
www.prnewswire.com/news-release...
Mayo Clinic researchers have uncovered why a distinct subset of lung adenocarcinomas mount a strong immune response and respond well to immune checkpoint inhibitors, pinpointing loss of a single tumor‑driving gene, PRKCI, as the key. #lungcancer
Mayo Clinic researchers identify why some lung tumors respond well to immunotherapy
In a new study published in Cell Reports, Mayo Clinic researchers have found several previously unknown genetic and cellular processes that occur in lung adenocarcinoma tumors that respond well to immunotherapy.
newsnetwork.mayoclinic.org
December 9, 2025 at 3:03 PM
Mayo Clinic researchers have uncovered why a distinct subset of lung adenocarcinomas mount a strong immune response and respond well to immune checkpoint inhibitors, pinpointing loss of a single tumor‑driving gene, PRKCI, as the key. #lungcancer
Interesting findings! Turning off ferroptosis suppressor protein 1 (FSP1) can shrink lung adenocarcinoma tumors by up to 80% in vivo, according to new data from NYU Langone Health published in Nature. #lungcancer
scitechdaily.com/turning-off-...
scitechdaily.com/turning-off-...
Turning Off This Protein Could Stop Lung Cancer in Its Tracks
Scientists at NYU Langone discovered that blocking a key protein that shields cancer cells from a natural stress-driven death process can dramatically slow lung tumor growth.
scitechdaily.com
December 8, 2025 at 3:03 PM
Interesting findings! Turning off ferroptosis suppressor protein 1 (FSP1) can shrink lung adenocarcinoma tumors by up to 80% in vivo, according to new data from NYU Langone Health published in Nature. #lungcancer
scitechdaily.com/turning-off-...
scitechdaily.com/turning-off-...
Lung cancer screening by low-dose CT in the US is preventing fewer than one-quarter of the deaths it could, according to new nationally representative modeling from the American Cancer Society. #lungcancer
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Lung Cancer Deaths Prevented and Life-Years Gained From Lung Cancer Screening
This study examines the current national prevalence of up-to-date lung cancer screening and estimates lung cancer deaths prevented and life-years gained from screening.
jamanetwork.com
December 7, 2025 at 3:01 PM
Lung cancer screening by low-dose CT in the US is preventing fewer than one-quarter of the deaths it could, according to new nationally representative modeling from the American Cancer Society. #lungcancer
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Universal age-based lung cancer screening from ages 40 to 85 could prevent more than 26,000 additional deaths annually, according to a new JAMA Network Open study from the Northwestern Medicine Canning Thoracic Institute. #lungcancer
news.feinberg.northwestern.edu/2025/11/25/n...
news.feinberg.northwestern.edu/2025/11/25/n...
New Study Shows Lung Cancer Surveillance in the United States Misses Most Patients; Northwestern Medicine Investigators Urge Universal Age-based Screening - News Center
In a new study of nearly 1,000 consecutive patients treated for lung cancer at Northwestern Medicine, investigators discovered only 35 percent would have qualified for screening according to the U.S.…
news.feinberg.northwestern.edu
December 6, 2025 at 3:02 PM
Universal age-based lung cancer screening from ages 40 to 85 could prevent more than 26,000 additional deaths annually, according to a new JAMA Network Open study from the Northwestern Medicine Canning Thoracic Institute. #lungcancer
news.feinberg.northwestern.edu/2025/11/25/n...
news.feinberg.northwestern.edu/2025/11/25/n...
Twenty years ago, there were few options for lung cancer patients. Now, clinicians at Baptist Health Miami Cancer Institute are reporting doubled survival rates driven by advances in robotic surgery and precision oncology. #lungcancer
baptisthealth.net/baptist-heal...
baptisthealth.net/baptist-heal...
Experts Discuss Life-Saving Advances in Lung Cancer Treatment
Twenty years ago, a lung cancer diagnosis offered limited options. Today, survival rates have doubled, and patients are living longer, healthier lives thanks to groundbreaking advances in both…
baptisthealth.net
December 5, 2025 at 3:03 PM
Twenty years ago, there were few options for lung cancer patients. Now, clinicians at Baptist Health Miami Cancer Institute are reporting doubled survival rates driven by advances in robotic surgery and precision oncology. #lungcancer
baptisthealth.net/baptist-heal...
baptisthealth.net/baptist-heal...
Higher glycemic index diets were associated with increased lung cancer risk in a large U.S. cohort, while higher glycemic load was associated with lower risk, according to a new analysis from the National Cancer Institute (NCI) PLCO Screening Trial.
Higher glycemic index linked to higher lung cancer risk
In a study appearing in The Annals of Family Medicine, researchers examined whether people who follow higher-GI or higher-GL diets have different risks of developing lung cancer. They used data from…
medicalxpress.com
December 4, 2025 at 3:02 PM
Higher glycemic index diets were associated with increased lung cancer risk in a large U.S. cohort, while higher glycemic load was associated with lower risk, according to a new analysis from the National Cancer Institute (NCI) PLCO Screening Trial.
REQORSA gene therapy from Genprex, Inc. has reported Acclaim-1 Phase 1 data in Clinical Lung Cancer, showing a clear RP2D, favorable safety, and durable disease control in EGFR-mutant NSCLC progressing on osimertinib. #lungcancer
www.prnewswire.com/news-release...
www.prnewswire.com/news-release...
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...
www.prnewswire.com
December 3, 2025 at 3:02 PM
REQORSA gene therapy from Genprex, Inc. has reported Acclaim-1 Phase 1 data in Clinical Lung Cancer, showing a clear RP2D, favorable safety, and durable disease control in EGFR-mutant NSCLC progressing on osimertinib. #lungcancer
www.prnewswire.com/news-release...
www.prnewswire.com/news-release...
This Giving Tuesday, help us change what it means to be diagnosed with lung cancer.
Your support today directly powers lung cancer science and brings us closer to making lung cancer a survivable disease. #lungcancer
Donate today! alcmi.org/join-us/dona...
Your support today directly powers lung cancer science and brings us closer to making lung cancer a survivable disease. #lungcancer
Donate today! alcmi.org/join-us/dona...
December 2, 2025 at 3:03 PM
This Giving Tuesday, help us change what it means to be diagnosed with lung cancer.
Your support today directly powers lung cancer science and brings us closer to making lung cancer a survivable disease. #lungcancer
Donate today! alcmi.org/join-us/dona...
Your support today directly powers lung cancer science and brings us closer to making lung cancer a survivable disease. #lungcancer
Donate today! alcmi.org/join-us/dona...
Congratulations to our friends at the Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard for the FDA approval of sevabertinib for HER2-mutant non-small cell lung cancer, a significant advancement for this patient group! #lungcancer
www.sciencedaily.com/releases/202...
www.sciencedaily.com/releases/202...
Blocking a single protein forces cancer cells to self-destruct
Researchers uncovered a powerful weakness in lung cancer by shutting down a protein that helps tumors survive stress. When this protein, FSP1, was blocked, lung tumors in mice shrank dramatically,…
www.sciencedaily.com
December 1, 2025 at 3:03 PM
Congratulations to our friends at the Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard for the FDA approval of sevabertinib for HER2-mutant non-small cell lung cancer, a significant advancement for this patient group! #lungcancer
www.sciencedaily.com/releases/202...
www.sciencedaily.com/releases/202...
NYU Grossman School of Medicine researchers led by Thales Papagiannakopoulos, PhD, report that lung adenocarcinoma becomes highly vulnerable when ferroptosis suppressor protein 1 (FSP1) is removed or inhibited. #lungcancer
www.sciencedaily.com/releases/202...
www.sciencedaily.com/releases/202...
Blocking a single protein forces cancer cells to self-destruct
Researchers uncovered a powerful weakness in lung cancer by shutting down a protein that helps tumors survive stress. When this protein, FSP1, was blocked, lung tumors in mice shrank dramatically,…
www.sciencedaily.com
November 30, 2025 at 3:01 PM
NYU Grossman School of Medicine researchers led by Thales Papagiannakopoulos, PhD, report that lung adenocarcinoma becomes highly vulnerable when ferroptosis suppressor protein 1 (FSP1) is removed or inhibited. #lungcancer
www.sciencedaily.com/releases/202...
www.sciencedaily.com/releases/202...
Lung cancer in people who have never smoked now represents an estimated 15% to 20% of all lung cancer cases, according to a recent study in JAMA and new data shared by Moffitt Cancer Center. #lungcancer
www.moffitt.org/endeavor/arc...
www.moffitt.org/endeavor/arc...
Lung Cancer Cases Rising in Nonsmokers
About 15% to 20% of lung cancer cases occur in those who have never smoked, like Sherry Haines
www.moffitt.org
November 29, 2025 at 3:01 PM
Lung cancer in people who have never smoked now represents an estimated 15% to 20% of all lung cancer cases, according to a recent study in JAMA and new data shared by Moffitt Cancer Center. #lungcancer
www.moffitt.org/endeavor/arc...
www.moffitt.org/endeavor/arc...
Loma Linda University Cancer Center’s Hamid Mirshahidi, MD, is bringing attention to the fact that lung cancer is rising in younger adults, including people who have never smoked, and our risk models and screening strategies are lagging behind. #lungcancer
Lung cancer is showing up in younger adults and smoking isn’t the only cause | News
Young people may overlook warning signs because they think they are not at risk.
news.llu.edu
November 28, 2025 at 3:01 PM
Loma Linda University Cancer Center’s Hamid Mirshahidi, MD, is bringing attention to the fact that lung cancer is rising in younger adults, including people who have never smoked, and our risk models and screening strategies are lagging behind. #lungcancer
To every patient who has enrolled in an ALCMI clinical trial—who has said yes to advancing science even as they face their own uncertain journey—we are profoundly grateful. #lungcancer #thankyou
November 27, 2025 at 3:03 PM
To every patient who has enrolled in an ALCMI clinical trial—who has said yes to advancing science even as they face their own uncertain journey—we are profoundly grateful. #lungcancer #thankyou
Congratulations to our friends at Amgen! The FDA has granted full approval to the company's IMDELLTRA (tarlatamab-dlle), the first therapy to demonstrate a Phase 3 overall survival benefit over chemotherapy in relapsed extensive stage small cell lung cancer (ES-SCLC). #lungcancer
FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER| Amgen
Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to Chemotherapy
www.amgen.com
November 26, 2025 at 3:02 PM
Congratulations to our friends at Amgen! The FDA has granted full approval to the company's IMDELLTRA (tarlatamab-dlle), the first therapy to demonstrate a Phase 3 overall survival benefit over chemotherapy in relapsed extensive stage small cell lung cancer (ES-SCLC). #lungcancer
Sevabertinib (Hyrnuo) has just received FDA accelerated approval as a targeted option for HER2-mutant NSCLC, backed by SOHO-01 data showing a 71% response rate in patients without prior HER2-directed therapy. #lungcancer
www.medpagetoday.com/hematologyon...
www.medpagetoday.com/hematologyon...
New FDA-Approved Option for HER2-Mutated Lung Cancer
Sevabertinib produced a 71% response rate in patients without prior HER2-targeted therapy
www.medpagetoday.com
November 25, 2025 at 3:02 PM
Sevabertinib (Hyrnuo) has just received FDA accelerated approval as a targeted option for HER2-mutant NSCLC, backed by SOHO-01 data showing a 71% response rate in patients without prior HER2-directed therapy. #lungcancer
www.medpagetoday.com/hematologyon...
www.medpagetoday.com/hematologyon...
RRAS and RRAS2 mutations have now been defined as recurrent, oncogenic, and potentially actionable drivers in NSCLC by investigators at Memorial Sloan Kettering Cancer Center. #lungcancer
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236
Introduction RRAS and RRAS2 encode a subfamily of RAS-like small GTPases that share considerable structural and functional similarities with KRAS , HRAS , and NRAS. Whether homologous RRAS / RRAS2…
www.biorxiv.org
November 24, 2025 at 3:02 PM
RRAS and RRAS2 mutations have now been defined as recurrent, oncogenic, and potentially actionable drivers in NSCLC by investigators at Memorial Sloan Kettering Cancer Center. #lungcancer
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...